Ferguson, J.J.

patient aspirin trial tranilast group aspirin dose disease placebo restenosi study death mortality event lotrafiban treatment stroke table aspirin doses hazard randomized platelet point robert /iiia placebo group circulation university end point angiographic swets subs service all-cause mortality figure heart david infarction revascularization result bravo follow-up ischemic vessel reduction cerebrovascular disease signi ficantly month hospital ն162 mg /day lotrafiban group outcome signi difference frequency cerebrovascular angiographic restenosis william effect ͻ162 mg /day laboratory glycoprotein all-cause lesion jeffrey analysis value target substudy michael topol stenosi creatinine dosing treatment groups efficacy 3 months 162 mg /d martin efficacy end point investigator artery ͻ0.001